Pancreatic Cancer Clinical Trials in Nashville

Showing 101-120 of 163 trials

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

NCT03205176

This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.

Malignant Solid TumorsLymphomaOvarian Cancer+3 more

AstraZeneca49 participantsStarted Jun 2017

Sarasota, Florida, United States • Oklahoma City, Oklahoma, United States • Nashville, Tennessee, United States +1 more locations

COMPLETEDPhase 3< 1 mile

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

NCT02923921

To compare the efficacy of pegilodecakin in combination with FOLFOX versus FOLFOX alone in participants with metastatic pancreatic cancer as measured by overall survival.

Pancreatic Cancer

Eli Lilly and Company567 participantsStarted Mar 2017

Gilbert, Arizona, United States • Goodyear, Arizona, United States • Phoenix, Arizona, United States +127 more locations

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

Pancreatic Cancer Trials in Other Cities

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer

Vaccine Study for Surgically Resected Pancreatic Cancer

Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer

A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Other Conditions in Nashville